ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor

ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor

Abstract Inflammatory myofibroblastic tumors are rare mesenchymal neoplasms frequently harboring oncogenic chromosomal rearrangements, most commonly, involving the ALK (anaplastic lymphoma kinase) gene. Treatment of this molecularly defined subgroup with the anaplastic lymphoma kinase inhibitor criz...

Full description

Bibliographic Details
Main Authors: Sebastian Y. F. Michels, Andreas H. Scheel, Thomas Wündisch, Johannes M. Heuckmann, Roopika Menon, Michael Puesken, Carsten Kobe, Helen Pasternack, Carina Heydt, Matthias Scheffler, Rieke Fischer, Anne M. Schultheis, Sabine Merkelbach-Bruse, Lukas Heukamp, Reinhard Büttner, Jürgen Wolf
Format: Article
Language:English
Published: Nature Publishing Group 2017-03-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-017-0004-3

Internet

https://doi.org/10.1038/s41698-017-0004-3

Similar Items